SU576898A3 - Способ снижени реактогенности гамма-глобулина - Google Patents
Способ снижени реактогенности гамма-глобулинаInfo
- Publication number
- SU576898A3 SU576898A3 SU7502306354A SU2306354A SU576898A3 SU 576898 A3 SU576898 A3 SU 576898A3 SU 7502306354 A SU7502306354 A SU 7502306354A SU 2306354 A SU2306354 A SU 2306354A SU 576898 A3 SU576898 A3 SU 576898A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- globulin
- gamma
- reducing
- reactogenesis
- precipitate
- Prior art date
Links
- 108010074605 gamma-Globulins Proteins 0.000 title description 7
- 238000000034 method Methods 0.000 title description 3
- 230000001413 cellular effect Effects 0.000 claims 1
- 229920002521 macromolecule Polymers 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- AZHSSKPUVBVXLK-UHFFFAOYSA-N ethane-1,1-diol Chemical compound CC(O)O AZHSSKPUVBVXLK-UHFFFAOYSA-N 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
(S4)
СПОСОБ СНИЖЕНИЯ РЕАКТОГЕННОСТИ ГАММАГЛОБУЛИНА
П р и м е р. В качестве исходного материала примен ют собранную плазму, которую смешивают этилового спирта и осаждают при температуре
-3°С и рН 7,2. При этом происходит осаждение фракции 1. Наход щуюс над осадком жидкость после этого при температуре и рН 5,8 смешивают с 10% этилового спирта. При этом происходит осаждение фрак1щй Н и III, которые состо т из гамма - глобулина. Осадок снова раствор ют и при рН 5 вновь производ т осаждение прибавлением 8% этилового спирта.
Из полученного над осадком раствора еще раз при рН 7,2 посредством прд{бавлени 25% этилового спирта производ т осаждение. Полученный осадок (фракци II) состоит на 90% из гамма глобулина,
Осадок гамма глобулина вновь раствор ют в буферном водном растворе при рН 6,7 в концентрации примерно 6%, причем к водному раствору прибавл ют примерно 10% оксиэтшпсрахмал. Оксиэтилкрахмал создает возможность произвести отделение уже имеющихс агрегированных щстиц и одновременно вызвать защиту еще неагрепфованного гамма глобулина.
После добавлени 10% полиэтиленгликол смесь центрифугируют. Полученный над осадком раствор при рН7,2 смешивают с 20% полиэтиленгликол и центрифугируют.
Ползчешшй осадок ввод т в физиологический раствор поваренной соли, получают раствор с концентрацией белка 5,2% и фильтруют в стерильных услови х.
Приготовленный раствор пригоден дл применени в терапевтических цел х.
Предлагаемый способ обеспечивает полное удаление всех других присутствукшщх в плазме веществ , в результате чего получают чистый гамма глобулин, который примен ют дл печени к профилакпоси инфекционных заболеваний.
Claims (1)
1. Мер-оке Альбертсон. Разделение клеточных часпщ и макромолекул, Москва, 1974.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2500076A DE2500076C3 (de) | 1975-01-02 | 1975-01-02 | Verfahren zur Gewinnung von intravenös-verträglichen Gammaglobulinen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU576898A3 true SU576898A3 (ru) | 1977-10-15 |
Family
ID=5935911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU7502306354A SU576898A3 (ru) | 1975-01-02 | 1975-12-31 | Способ снижени реактогенности гамма-глобулина |
Country Status (20)
| Country | Link |
|---|---|
| JP (1) | JPS5512001B2 (ru) |
| AT (1) | AT344883B (ru) |
| AU (1) | AU505416B2 (ru) |
| BE (1) | BE837211A (ru) |
| CA (1) | CA1058075A (ru) |
| DD (1) | DD121875A5 (ru) |
| DE (1) | DE2500076C3 (ru) |
| DK (1) | DK144679C (ru) |
| EG (1) | EG11987A (ru) |
| ES (1) | ES443982A1 (ru) |
| FR (1) | FR2296429A1 (ru) |
| GB (1) | GB1495159A (ru) |
| IE (1) | IE43449B1 (ru) |
| IL (1) | IL48766A (ru) |
| IN (1) | IN143525B (ru) |
| NL (1) | NL179824C (ru) |
| PL (1) | PL99599B1 (ru) |
| SE (1) | SE437470B (ru) |
| SU (1) | SU576898A3 (ru) |
| ZA (1) | ZA758050B (ru) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2604759C2 (de) * | 1976-02-07 | 1983-06-01 | SCHURA Blutderivate GmbH & Co KG, 4150 Krefeld | Verfahren zur Gewinnung von iv-verträglichen Γglobulinen |
| JPS6016406B2 (ja) * | 1976-08-06 | 1985-04-25 | マイヤ−、ル−イス、コ−バル | 静脈内に投与可能なガンマ・グロブリンの製造法ならびにそれにより調製したガンマ・グロブリン |
| US4124576A (en) * | 1976-12-03 | 1978-11-07 | Coval M L | Method of producing intravenously injectable gamma globulin |
| GB1603244A (en) * | 1977-05-20 | 1981-11-18 | Max Planck Gesellschaft | Medicaments for the suppression of pathological processes |
| JPS5822085B2 (ja) * | 1977-07-19 | 1983-05-06 | 株式会社ミドリ十字 | 静注用ガンマ・グロブリン製剤 |
| AT359641B (de) * | 1978-09-19 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates |
| EP0019403B1 (en) * | 1979-05-10 | 1985-07-31 | American Hospital Supply Corporation | Hydroxyalkyl-starch drug carrier |
| US4396608A (en) * | 1981-08-24 | 1983-08-02 | Cutter Laboratories | Intravenously injectable immune serum globulin |
| EP0085747B2 (de) * | 1982-02-08 | 1990-05-30 | Schweizerisches Serum- und Impfinstitut und Institut zur Erforschung der Infektionskrankheiten | Intravenös verabreichbares humanes Immunglobulin und Verfahren zu dessen Herstellung |
| US4482483A (en) * | 1983-04-06 | 1984-11-13 | Armour Pharmceutical Company | Composition of intravenous immune globulin |
| SE8302483L (sv) * | 1983-05-02 | 1984-11-03 | Pharmacia Ind | Forfarande vid rening av biologiskt aktiva substanser |
| US5945098A (en) * | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
| DE19907257A1 (de) * | 1999-02-21 | 2000-09-14 | Bernd Horst Meier | Mittel zur Steuerung der Diffusion von Injektionslösungen |
| DE10040707A1 (de) * | 2000-08-17 | 2002-03-14 | Braun Melsungen Ag | Kolloidale Pharmakomodulation injizierter Arzneimittel |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| JP5475994B2 (ja) | 2005-11-30 | 2014-04-16 | アッヴィ・インコーポレイテッド | 抗Ａβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。 |
| KR101439828B1 (ko) | 2005-11-30 | 2014-09-17 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE348942B (ru) * | 1970-06-02 | 1972-09-18 | Statens Bakteriologiska Labor | |
| DE2234069A1 (de) * | 1971-07-16 | 1973-02-08 | South African Inventions | Verfahren zur herstellung eines gereinigten gamma-globulins |
| IL43643A (en) * | 1972-11-27 | 1976-10-31 | Baxter Laboratories Inc | Method for production of gamma globulin |
| JPS49101516A (ru) * | 1973-01-13 | 1974-09-25 |
-
1975
- 1975-01-02 DE DE2500076A patent/DE2500076C3/de not_active Expired
- 1975-12-16 NL NLAANVRAGE7514627,A patent/NL179824C/xx not_active IP Right Cessation
- 1975-12-18 SE SE7514388A patent/SE437470B/xx not_active IP Right Cessation
- 1975-12-22 DK DK584375A patent/DK144679C/da active
- 1975-12-23 AT AT981675A patent/AT344883B/de active
- 1975-12-26 FR FR7539814A patent/FR2296429A1/fr active Granted
- 1975-12-27 JP JP15974275A patent/JPS5512001B2/ja not_active Expired
- 1975-12-29 GB GB53020/75A patent/GB1495159A/en not_active Expired
- 1975-12-29 DD DD190614A patent/DD121875A5/xx unknown
- 1975-12-30 BE BE6045314A patent/BE837211A/xx not_active IP Right Cessation
- 1975-12-30 IE IE2826/75A patent/IE43449B1/en unknown
- 1975-12-30 IN IN2413/CAL/75A patent/IN143525B/en unknown
- 1975-12-30 CA CA242,734A patent/CA1058075A/en not_active Expired
- 1975-12-30 EG EG775/75A patent/EG11987A/xx active
- 1975-12-30 ZA ZA00758050A patent/ZA758050B/xx unknown
- 1975-12-30 IL IL48766A patent/IL48766A/xx unknown
- 1975-12-30 AU AU87921/75A patent/AU505416B2/en not_active Expired
- 1975-12-30 ES ES443982A patent/ES443982A1/es not_active Expired
- 1975-12-31 SU SU7502306354A patent/SU576898A3/ru active
-
1976
- 1976-01-01 PL PL1976186289A patent/PL99599B1/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AT344883B (de) | 1978-08-10 |
| CA1058075A (en) | 1979-07-10 |
| FR2296429B1 (ru) | 1978-12-01 |
| BE837211A (fr) | 1976-06-30 |
| AU8792175A (en) | 1977-07-14 |
| FR2296429A1 (fr) | 1976-07-30 |
| AU505416B2 (en) | 1979-11-22 |
| DK144679B (da) | 1982-05-10 |
| DE2500076C3 (de) | 1982-11-18 |
| DK584375A (da) | 1976-07-03 |
| SE7514388L (sv) | 1976-07-05 |
| NL179824B (nl) | 1986-06-16 |
| GB1495159A (en) | 1977-12-14 |
| JPS5512001B2 (en) | 1980-03-29 |
| ES443982A1 (es) | 1977-07-16 |
| PL99599B1 (pl) | 1978-07-31 |
| NL179824C (nl) | 1986-11-17 |
| NL7514627A (nl) | 1976-07-06 |
| IN143525B (ru) | 1977-12-17 |
| ATA981675A (de) | 1977-12-15 |
| SE437470B (sv) | 1985-03-04 |
| DE2500076A1 (de) | 1976-07-08 |
| JPS5191321A (en) | 1976-08-10 |
| DK144679C (da) | 1982-10-11 |
| IL48766A0 (en) | 1976-02-29 |
| IE43449B1 (en) | 1981-02-25 |
| EG11987A (en) | 1981-12-31 |
| IE43449L (en) | 1976-07-02 |
| IL48766A (en) | 1979-11-30 |
| DE2500076B2 (de) | 1979-02-22 |
| DD121875A5 (ru) | 1976-09-05 |
| ZA758050B (en) | 1976-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU576898A3 (ru) | Способ снижени реактогенности гамма-глобулина | |
| Börjeson et al. | STUDIES ON HUMAN PERIPHERAL BLOOD LYMPHOCYTES IN VITRO: I. Biological and Physicochemical Properties of the Pokeweed Mitogen | |
| Marler et al. | The polypeptide chains of rabbit γ-globulin and its papain-cleaved fragments | |
| Van der Geld et al. | Reactivity of Myasthenia Gravis Serum γ-Globulin with Skeletal Muscle and Thymus Demonstrated by Immunofluoirescence. | |
| FR2372841A1 (fr) | Gamma-globuline injectable par voie intraveineuse | |
| Singer et al. | A general method for the isolation of antibodies | |
| EA199700143A1 (ru) | Способ и композиция ждя липидизации гидрофильных молекул | |
| Kodama et al. | Plane xanthomatosis with antilipoprotein autoantibody | |
| Nisonoff et al. | Effect of hydrolysis by papain on the combining sites of an antibody | |
| SU638243A3 (ru) | Способ очистки гамма- -глутамилтаурина | |
| Libretti et al. | Precipitin analysis of C-reactive protein by gel diffusion. | |
| Rimington et al. | Comparison of the globoglycoid, crystalbumin, seroglycoid and seromucoid fractions of normal horse serum | |
| Hardwicke et al. | Human α1-glycoproteins Separation from pathological urine and examination by immunological and electrophoretic methods | |
| Gordon et al. | Electrophoresis of proteins in agar jelly | |
| GB1476103A (en) | Method for the separation of chlorophyll | |
| Serra | Cytochemical demonstration of masked lipids | |
| Zlotnick et al. | Immunoelectrophoresis of Serum in Progressive Systemic Sclerosis (Diffuse Scleroderma). | |
| McCasland et al. | Synthesis of Sulfur Analogs of Inositol (Dimercaptocyclohexanetetrols). Nuclear Magnetic Resonance Configurational Proofs1, 2 | |
| SU642331A1 (ru) | Композици дл получени пленок | |
| SU1109170A1 (ru) | Способ получени иммуноглобулина | |
| ES416726A1 (es) | Procedimiento para aislar un antigeno de polipeptido aso- ciado con el cancer. | |
| CN104479005B (zh) | 一种促性腺激素纯化的方法 | |
| GB1441752A (en) | Preparation of human or other purified albumin | |
| DE2708780A1 (de) | Neue blutserumpraeparationen, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und medizinische hilfsstoffe | |
| Van Den Berg et al. | Homogeneous antibodies in lethally irradiated and autologous bone marrow reconstituted Rhesus monkeys |